New Plasma Protein Signature Identified for Ankylosing Spondylitis Damage
A recent study reveals a five-protein plasma signature linked to significant structural damage in ankylosing spondylitis patients.
A five-protein plasma signature correlates with high structural damage in ankylosing spondylitis.
The study involved 176 participants, including controls and patients with varying damage levels.
The findings suggest a potential noninvasive biomarker to enhance imaging assessments.
Researchers have identified a five-protein plasma signature associated with severe structural damage in patients suffering from ankylosing spondylitis (AS). This discovery, stemming from a study involving 176 participants, indicates that these plasma protein signatures could serve as valuable complements to traditional imaging techniques, capturing biological processes that extend beyond systemic inflammation.
The study aimed to address the limitations of current inflammatory markers in assessing structural damage in AS, as pathological bone formation is not fully represented by systemic inflammation. To achieve this, researchers conducted deep plasma proteomics in a discovery cohort of 88 individuals, which included 32 healthy controls and patients categorized based on the SPARCC sacroiliac joint structural score into high and low damage groups.
Through advanced analytical techniques, including age- and sex-adjusted differential expression analysis and integrated machine learning, the team identified five candidate proteins: ITGA2B, HSPG2, ITGB1, EPHB2, and SAA2. These proteins were validated in a separate cohort of 88 participants, demonstrating a strong performance with an area under the curve (AUC) of 0.917, significantly surpassing the performance of individual biomarkers.
The implications of this research extend beyond individual patient assessments. The validated five-protein panel offers a noninvasive method for identifying patients with high structural damage, potentially improving clinical decision-making. Furthermore, the findings suggest a dual-pathway model in AS, where systemic inflammation and platelet-ECM remodeling are interconnected yet partially dissociated, indicating the complexity of the disease.
Future studies with larger cohorts are necessary to further validate these findings and explore the clinical applications of the identified plasma protein signatures. This research represents a significant advancement in understanding ankylosing spondylitis and may pave the way for improved diagnostic and treatment strategies.
